Furthermore, in male breast cancer patients, individualized risk–benefit assessments may support the substitution of aromatase inhibitors plus gonadotropin-releasing hormone analogues when the thrombotic risk is deemed excessive. This evidence concerns the gene CYP19A1 and breast carcinoma.